Press Release|

SHL Medical’s COVID-19 statement

Virus 1760x420

In response to the global effect of the Coronavirus (COVID-19), SHL Medical has taken proactive measures to protect the health and safety of our colleagues and ensure the continuity of business operations for our customers. As a world-leading provider of autoinjectors for major pharmaceutical companies worldwide, we are also committed to ensuring supply for the end-users of our customer’s drug delivery products.

SHL officially deployed precautionary measures in January and has since been closely monitoring the situation on a continuous basis. Our measures encompass both our business operations and employee health.

Click here to read our full response statement.

About SHL Medical

SHL Medical is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery systems such as autoinjectors, pen injectors and advanced inhaler systems. We offer final assembly, labeling, and packaging solutions for our drug delivery devices, and also provide contract manufacturing and engineering services for the production of complex medtech and industrial products.

With locations in Switzerland, Taiwan, Sweden, and the US, our experienced engineers and designers develop product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

For additional information, visit

Media contact:   

Related News